The Ultrasound TAM Mirage: Why Billions Haven’t Unlocked Outpatient POCUS Scale
Point-of-Care Ultrasound (POCUS) Transformed Hospitals. Why Hasn’t It Scaled in Outpatient Care?
Point-of-care ultrasound hasproven valuable in emergency medicine and critical care. In emergency departments and ICU, POCUS is now routine and used to diagnose pneumothorax, check cardiac function, evaluate undifferentiated shock, guide vascular access, and accelerate decision-making in ways that are both evidence-based and operationally indispensable. The clinical utility is real. The technology works.
And yet, despite hospital success and an estimated $3–6 billion invested across handheld hardware and AI-enabled ultrasound platforms over the past decade, POCUS has not achieved comparable scale in outpatient care.
That divergence is not a technology failure.
It is a commercial architecture failure.
The Denominator Illusion
Total addressable market (TAM) models typically begin with a clean equation: number of clinicians multiplied by patient visits multiplied by attach rate. The implication is straightforward. If ultrasound is portable, affordable, and AI-assisted, then nearly every outpatient clinician becomes a potential imaging node.
But the real denominator is not "all outpatient clinicians who could benefit from just having an handheld ultrasound probe in hand."
Rather the value is only unlocked for clinicians practicing in revenue-cycle mature environments, with imaging quality assurance governance, CPT-concordant documentation workflows, payer policy alignment, and without destabilizing internal referral economics (where reimbursement is better for standard imaging).
Thus that outpatient group who can benefit is materially smaller.
The TAM assumes frictionless reimbursement. The outpatient ecosystem is anything but frictionless.
CPT and Medical Policy Were Not Built for Handheld Workflows
Most ultrasound CPT codes were constructed around comprehensive diagnostic studies performed in formal imaging environments. They assume defined view sets, structured interpretation standards, and department-level archiving and compliance processes. Payer medical policies were written within that same architectural understanding and many do not even contemplate the presence of POCUS. Some could argue there are no CPT codes reflective of POCUS, only for full ultrasound. Beyond that there are frequency limits, medical necessity criteria, and site-of-service assumptions reflect an imaging department model...a far cry from a handheld, AI-guided, AI-Post-Processed, and clinician-performed workflow embedded in a 15-minute visit.
In some health plans, certain ultrasound studies also require prior authorization. If a handheld POCUS exam is performed without navigating that requirement, reimbursement denial risk is predictable. If documentation does not meet defined view expectations, downcoding is predictable. If medical necessity is not explicit in the record, payer recoupment risk is predictable.
These are not edge cases. They are structural features of the outpatient payment system.
Yet many MedTech manufacturers behave as though existing CPT codes are inherently sufficient. Few have engaged payers to evolve medical policy language to reflect handheld workflows. Few design product requirements explicitly around audit and reimbursement defensibility. Few model denial rates as a core commercialization variable.
Reimbursement was not "addressed later." It might be assumed that it was never comtemplated and engineered into the product strategy.
Ultrasound outside hospital walls is not a device sale. It is a payment-governed diagnostic service, but commercial approaches have yet to evolve.
The Sonographer Shortage Narrative Is Economically Incomplete
It is true that sonographer capacity is constrained in the United States and Internationally. In emergency and critical care settings, POCUS has mitigated that constraint in time-sensitive environments where throughput and acuity justify workflow friction.
But expanding user bases beyond a sonographer via AI guidance in an outpatient clinic does not eliminate standard view requirements, image quality needs, documentation requirements, quality oversight, interpretation liability, denial management, or prior authorization workflows. It shifts the burden.
Labor substitution does not automatically create scalable margin. When clinician time expands to meet documentation standards and effective reimbursement is reduced by bundling, denials, or policy edits, already brittle unit economics become more fragile. If a family physician spends 12-15 minutes performing and documenting a limited study that reimburses at $50-80 after payer edits, the effective hourly rate may be lower than baseline E&M work and that is before accounting for denial risk.
The "math ain't mathing" in fee-for-service outpatient environments.
The Incentive Conflict Under Fee-for-Service
Under fee-for-service payment, comprehensive imaging studies frequently reimburse at higher rates than limited POCUS exams. Referral-based imaging supports specialist economics. In many systems, POCUS is substitutional rather than additive and may be more of a quick look before full imaging, but jusitifiable business cases are often absent.
Reducing downstream imaging is clinically rational. It may represent system-level savings. But unless the performing entity bears risk or shares in those savings, it may represent local revenue erosion.
The language of value-based care appears frequently in pitch decks. But without modeling who captures economic value, it remains rhetoric. Care enablement "potential" does not automatically translate into financial sustainability.
Why POCUS Scaled in Hospitals
The contrast with hospital adoption is instructive. Emergency departments and ICUs already operate within institutional infrastructures that support archiving, QA, compliance, and billing. Facility economics absorb variability in professional reimbursement and operate under DRG structures. Time-sensitive decisions justify operational friction and internal cannibalization is minimal.
Payment architecture supported scale.
Outpatient environments lack that structural alignment.
Billions Invested, and Still No Escape Velocity
Disclosed venture capital across handheld and AI ultrasound companies exceeds $1.5 billion. When OEM R&D, commercialization infrastructure, and platform development are considered, ecosystem investment plausibly reaches $3–6 billion over the past decade.
If that level of capital has not unlocked broad outpatient scale despite strong evidence that POCUS changes clinical management in a substantial proportion of encounters, then the limiting factor is not probe engineering.
It is revenue-cycle design.
It is payer engagement.
It is utilization management alignment.
It is business model innovation.
The industry advanced image acquisition and image quality. It has not yet solved monetization of its R&D beyond the walls of the hospital.
The Real TAM
Ultrasound technology is ready. The evidence base is substantial. The care enablement potential in outpatient settings is meaningful.
But the true addressable market is constrained to settings that can:
- Capture reimbursement defensibly
- Navigate prior authorization requirements
- Survive audit scrutiny
- Maintain governance infrastructure
- Align incentives around avoided downstream utilization
That defines the real denominator.
A full solution in the outpatient include not only the Probe, but training, credentialing, PACS, reporting, readers, QA, management pathways, and much more. Until product development is engineered around what a full solutionneeds to enable payment architecture, value-chain economics, and policy engagement from inception (not bolted on after commercialization), then outpatient projections will remain theoretical, suboptimal and visionary about what could be.
Handheld POCUS has the potential to reshape ambulatory and post-acute medicine, but probes and AI alone will not deliver escape velocity.
Scale in healthcare is governed by economics.
And economics require design.
------------------------------------------------------------------------
Follow on for Part 2, where I examine specific use cases where AI investment may be misaligned and also highlight the one potential application where payment architecture, clinical guidelines, and market gaps align perfectly...its just waiting for the MedTech development.